Stefan Heller just got back to me.
I asked him about Dr. Shim and mentioned PRP injections, but no details about the cocktail.
"Listen to your otologist. I know that Minbo stayed in my lab, and some meetings, but he received no training and we did not provide him with any secrets to cure hearing loss. There is no scientific foundation that would show any of the treatments you have mentioned work. I am not able to recommend
Sincerely,
Stefan Heller"
I can't cut and paste on my kids tablet, that's what I am using now. That is the gist of it.
Don't know what to say, I thought the Heller lab was doing work like this, I am gutted and confused. Will check email now to make sure I didn't miss anything.
Well, there is indication that this will work. I've posted a peer reviewed paper about IGF-1 (several times) that touts clinical phase studies on humans that implicated it in regeneration of hair cells as well as recovery of hearing IN HUMANS. PRP contains IGF-1. as well as other growth factors, he also used mesenchymal stem cells and Stefan Hellar himself has his name on a published paper saying those types of stem cells are proginitors for hair cells, at least in vitro. So there is evidence that this does actually work.
Human trial overview:
"clinical trials were performed to study the efficacy of IGF1 in the treatment of SSHL.
First, a phase I/II clinical trial was performed to assess the safety and efficacy of IGF1 (UMIN-CTRR000000936) (Nakagawa et al., 2012, 2010). SSHL that was refractory to systemic steroid therapy was selected as the target disease for the clinical trial. Patients (n ¼ 25) with definite SSHL and with no recovery after systemic glucocorticoid treatment for more than 7 days were recruited within 29 days of SSHL onset. T he outcome of IGF1 treatment in patients was compared with that of a historical control in which patients underwent hyperbaric oxygen therapy. In the historical control, 66 out of 199 patients (33%) exhibited improvements in hearing threshold (Nakagawa et al., 2012, 2010). The outcome measure was the proportion of patients showing an improvement in hearing threshold, which was defined as a recovery of 10 decibel (dB) hearing level (HL) in the mean hearing level at the five frequencies tested (0.25, 0.5, 1, 2, and 4 kHz) at 12 and 24 weeks after treatment. Topical IGF1 application onto the round window membrane via gelatin hydrogels was performed as in the in vivo animal studies (Fujiwara et al., 2008; Iwai et al., 2006; Lee et al., 2007) and at 12 weeks after the test treatment, 48% (95% confidence interval［CI］28e69%) of the patients exhibited improved K. Yamahara et al. / Hearing Research 330 (2015) 2e9 5 hearing, with this proportion increasing to 56% (95% CI 35e76%) at 24 weeks after treatment. The proportion of hearing improvement observed at 24 weeks after IGF1 treatment was significantly higher than that observed in the historical control trial (p ¼ 0.015) (Nakagawa et al., 2010). The average recovery in pure tone audiometry thresholds over the five frequencies tested was found to be 11.9 dB (Nakagawa et al., 2012). Hearing improvement at 24 weeks after IGF1 treatment was found to be statistically significant at all five frequencies compared with the hearing levels of the patients at registration. A time course analysis of the changes in hearing threshold revealed that
hearing recovery after topical IGF1 treatment occurred during the initial 4 weeks in the majority of patients, but that further recovery (>20 dB) was evident in some patients at a later stage (Nakagawa et al., 2012)
. No serious adverse events associated with the test treatment occurred during this trial."
Then they did another human clinical trial with even better results!!!!
"Based on the result of the phase I/II clinical trial described in 5.1., a randomized clinical study was performed (UMIN000004366)."
"A trend, however, was observed: a higher proportion of patients with
30 dB HL improvements in pure-tone average hearing thresholds was measured for the IGF1 group than in that the intra-tympanic steroids group. The difference in changes in pure-tone average hearing thresholds over time between the two treatment groups was found to be statistically significant (p ＝ 0.003). In this trial, no adverse events were observed. The findings of this trial suggest that IGF1 is an effective treatment for SSHL and that IGF1 is a similar or superior therapy compared with intra-tympanic Dex therapy."
CONCLUSION:
"In this review, IGF1 has been described as a novel and
potent treatment for SNHL, potentially via HC protection and regeneration."
SOURCE:
Insulin-like growth factor 1: A novel treatment for the protection or
regeneration of cochlear hair cells
Kohei Yamahara, Norio Yamamoto, Takayuki Nakagawa, Juichi Ito
There's more significant data for this than FX322 and in terms of curing tinnitus as a symptom of hearing loss this is by far the best thing I think we have seen so far.
Someone find something better, please.
Member
